An increasing trend is found in using TLR agonists as potential built-in adjuvants for the development of novel vaccines.
← all excerpts
Deep survey for designing a vaccine against SARS-CoV-2 and its new mutations.
1
—
—
An increasing trend is found in using TLR agonists as potential built-in adjuvants for the development of novel vaccines.